230 related articles for article (PubMed ID: 34101217)
1. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.
Wang J; Ma J; Cai C; Daver N; Ning J
Stat Med; 2021 Sep; 40(21):4629-4639. PubMed ID: 34101217
[TBL] [Abstract][Full Text] [Related]
2. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
Sambucini V
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
[TBL] [Abstract][Full Text] [Related]
3. Comparison of futility monitoring guidelines using completed phase III oncology trials.
Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
[TBL] [Abstract][Full Text] [Related]
4. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
5. Comparing Bayesian early stopping boundaries for phase II clinical trials.
Jiang L; Yan F; Thall PF; Huang X
Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
[TBL] [Abstract][Full Text] [Related]
7. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall PF; Simon RM; Estey EH
J Clin Oncol; 1996 Jan; 14(1):296-303. PubMed ID: 8558211
[TBL] [Abstract][Full Text] [Related]
8. Interpreting a Bayesian phase II futility clinical trial.
Beall J; Cassarly C; Martin R
Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian adaptive design for clinical trials of rare efficacy outcomes with multiple definitions.
Golchi S; Willard JJ; Pullenayegum E; Bassani DG; Pell LG; Thorlund K; Roth DE
Clin Trials; 2022 Dec; 19(6):613-622. PubMed ID: 36408565
[TBL] [Abstract][Full Text] [Related]
10. Statistical rules for safety monitoring in clinical trials.
Martens MJ; Logan BR
Clin Trials; 2024 Apr; 21(2):152-161. PubMed ID: 37877375
[TBL] [Abstract][Full Text] [Related]
11. Optimal timing for an accelerated interim futility analysis incorporating real world data.
Haine LMF; Murray TA; Koopmeiners JS
Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
[TBL] [Abstract][Full Text] [Related]
12. Over-accrual in Bayesian adaptive trials with continuous futility stopping.
Barrado LG; Burzykowski T
Clin Trials; 2023 Jun; 20(3):252-260. PubMed ID: 36803007
[TBL] [Abstract][Full Text] [Related]
13. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
14. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
15. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
16. Two-stage seamless transition design from open-label single-arm to randomized double-arm clinical trials.
Shi H; Yin G
Stat Methods Med Res; 2018 Jan; 27(1):158-171. PubMed ID: 28034171
[TBL] [Abstract][Full Text] [Related]
17. A randomized Bayesian optimal phase II design with binary endpoint.
Ding Y
J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
[TBL] [Abstract][Full Text] [Related]
18. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.
Pedroza C; Tyson JE; Das A; Laptook A; Bell EF; Shankaran S;
Trials; 2016 Jul; 17(1):335. PubMed ID: 27450203
[TBL] [Abstract][Full Text] [Related]
19. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
Wason JM; Trippa L
Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations.
Asano J; Hirakawa A
Pharm Stat; 2020 Nov; 19(6):975-1000. PubMed ID: 32779393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
